» Articles » PMID: 20574151

MiRNA-520b and MiR-520e Sensitize Breast Cancer Cells to Complement Attack Via Directly Targeting 3'UTR of CD46

Overview
Specialties Oncology
Pharmacology
Date 2010 Jun 25
PMID 20574151
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs), non-coding RNAs that function as post-transcriptional gene regulators, play a pivotal role in cancer development. In the present study, we elucidated the roles of miR-520b and miR-520e in breast cancer cells. We examined the expression levels of miR-520b and miR-520e in the immortalized breast cell line, HBL-100, and in three breast cancer cell lines: MCF-7, LM-MCF-7 and MDA-MB-231. We show the expression levels of miR-520b and miR-520e in the breast cancer cell lines were lower than that in the HBL-100 cells. Furthermore, the breast cancer cell lines showed less sensitivity to complement-dependent cytotoxicity (CDC). We found that overexpression of miR-520b and miR-520e increases the sensitivity of the breast cancer cells to CDC, whereas further suppression of miR-520b and miR-520e decreases the sensitivity of the breast cancer cells to CDC. We then demonstrate that miR-520b and miR-520e are able to directly target the 3'untranslated regions (3'UTR) of the membrane-bound complement regulatory protein CD46; suggesting that miR-520b and miR-520e down-regulate CD46 at post-transcriptional level. Enzyme-linked immunosorbent assay (ELISA) showed that overexpression of miR-520b and miR-520e results in the increased expression of C3b, which is mediated by downregulated CD46. These results suggest that miRNA-520b and miR-520e mediated down-regulation of CD46 induces opsonization of cancer cells via an alternative pathway resulting in complement activation. Thus, we conclude that miR-520b and miR-520e contribute to CDC in breast cancer cells via directly targeting the 3'UTR of CD46.

Citing Articles

Expression study of microRNA cluster on chromosome 19 (C19MC) in tumor tissue and serum of breast cancer patient.

Altalebi S, Haghi M, Feizi M Mol Biol Rep. 2023; 50(12):9825-9831.

PMID: 37840066 DOI: 10.1007/s11033-023-08801-x.


Advancing Breast Cancer Heterogeneity Analysis: Insights from Genomics, Transcriptomics and Proteomics at Bulk and Single-Cell Levels.

Zhu Z, Jiang L, Ding X Cancers (Basel). 2023; 15(16).

PMID: 37627192 PMC: 10452610. DOI: 10.3390/cancers15164164.


Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications.

Papadakos S, Stergiou I, Gkolemi N, Arvanitakis K, Theocharis S Cancers (Basel). 2023; 15(13).

PMID: 37444544 PMC: 10340246. DOI: 10.3390/cancers15133434.


Let-7b-5p inhibits colon cancer progression by prohibiting APC ubiquitination degradation and the Wnt pathway by targeting NKD1.

Dai Y, Liu J, Li X, Deng J, Zeng C, Lu W Cancer Sci. 2022; 114(5):1882-1897.

PMID: 36445120 PMC: 10154867. DOI: 10.1111/cas.15678.


Dysregulated miRNAs network in the critical COVID-19: An important clue for uncontrolled immunothrombosis/thromboinflammation.

Mortazavi-Jahromi S, Aslani M Int Immunopharmacol. 2022; 110:109040.

PMID: 35839566 PMC: 9271492. DOI: 10.1016/j.intimp.2022.109040.